Physician profile
Justin Thrush
NPI 1336778018
$2,030.74
in general payments reported to CMS, 2019-2025
15 companies · $84.16 in 2025
The $84.16 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $456 · 2023: $531 · 2024: $720 · 2025: $84.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $421.72 | 2022-2024 | Libtayo |
| Abbvie INC. | $395.09 | 2021-2023 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $196.02 | 2023-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $151.99 | 2022-2024 | |
| Mimedx Group, INC. | $130.76 | 2024 | |
| Krystal Biotech INC | $124.99 | 2023 | Vyjuvek |
| Organogenesis INC. | $120.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.03 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $112.07 | 2021 | |
| Genzyme Corporation | $52.10 | 2022-2023 | |
| Amgen INC. | $51.83 | 2023-2024 | Otezla |
| Incyte Corporation | $47.34 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $43.08 | 2023 | Valchlor |
| Janssen Biotech, INC. | $42.52 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $23.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Thrush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.